

Short profile

Name: Qritive Pte Ltd

Medical field	Oncology/Pathology
Product type	AI/Software-based Diagnostic Tool — specifically Software as a Medical Device (SaMD) / Clinical Decision Support Software
Growth stage	Commercials, Products deployed live for customers
Team	9

Description of product:

AI models which can predict patient survival probability and PD-L1 tumor proportion score directly from standard H&E slides. By eliminating the need for immunohistochemistry (IHC) for low-risk cases, these models offer a cost-effective screening alternative for patients who cannot afford advanced testing or for healthcare settings where IHC is unavailable.



Bruno.occhipinti
@qritive.com



+65 98777905



www.qritive.com

Desired project goal:

This study evaluates whether an AI model trained on multiplex immunofluorescence (mIF) can extract prognostic morphological features directly from H&E images for patient screening, using Charité's paired H&E/mIF NSCLC cohort (Schallenberg et al., 1,168 patients) where both modalities were generated from the same physical tissue sections.

Please also elaborate on the primary outcome

The primary outcome is the degree of concordance between H&E-only predictions and the mIF-derived reference standard for both survival probability and PD-L1 TPS, measured on the same patients and same tissue sections.

DR. HANA HASTOR, Medical Advisor CBI
hana.hastor@bih-charite.de